These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. Rosenbaum E; Carducci MA Expert Opin Pharmacother; 2003 Jun; 4(6):875-87. PubMed ID: 12783585 [TBL] [Abstract][Full Text] [Related]
5. Current trials using bone-targeting agents in prostate cancer. Tu SM; Lin SH Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481 [TBL] [Abstract][Full Text] [Related]
9. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. van Moorselaar RJ; Voest EE Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818 [TBL] [Abstract][Full Text] [Related]
11. Treatment options in hormone-refractory prostate cancer: current and future approaches. Harris KA; Reese DM Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129 [TBL] [Abstract][Full Text] [Related]
12. New drugs in prostate cancer. Armstrong AJ; Carducci MA Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849 [TBL] [Abstract][Full Text] [Related]
13. The biology of hormone refractory prostate cancer. Why does it develop? Isaacs JT Urol Clin North Am; 1999 May; 26(2):263-73. PubMed ID: 10361549 [TBL] [Abstract][Full Text] [Related]
14. Management of prostate cancer. Part 3: metastatic disease. Shah J; Khaksar SJ; Sooriakumaran P Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171 [TBL] [Abstract][Full Text] [Related]
15. Antiangiogenesis: a possible treatment option for prostate cancer? Longoria RL; Cox MC; Figg WD Clin Genitourin Cancer; 2005 Dec; 4(3):197-202. PubMed ID: 16425989 [TBL] [Abstract][Full Text] [Related]
16. [Therapy of hormone refractory prostate cancer: new standards, new trends]. Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408 [TBL] [Abstract][Full Text] [Related]
17. Management of patients with hormone refractory prostate cancer. Muthuramalingam SR; Patel K; Protheroe A Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):505-16. PubMed ID: 15630842 [TBL] [Abstract][Full Text] [Related]
19. Angiogenesis as a strategic target for prostate cancer therapy. Li Y; Cozzi PJ Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic options for hormone-refractory prostate cancer in 2007. Hadaschik BA; Gleave ME Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]